Home/Pipeline/NVK029

NVK029

Presbyopia

Phase 2Active

Key Facts

Indication

Presbyopia

Phase

Phase 2

Status

Active

Company

Vyluma

About Vyluma

Vyluma is a clinical-stage biotech founded in 2020, headquartered in Bridgewater, New Jersey. Its lead candidate, NVK002, is a low-dose atropine eye drop in late-stage development to slow the progression of pediatric myopia, positioning it to potentially be the first FDA-approved pharmaceutical treatment for this condition. The company has a broader pipeline targeting other prevalent vision disorders like presbyopia and night vision disturbance, leveraging its expertise in topical ophthalmic formulations. Vyluma operates as a private, pre-revenue company aiming to transform the standard of care in ophthalmology.

View full company profile

Therapeutic Areas

Ophthalmology Pediatric Myopia Refractive Errors

Other Presbyopia Drugs

Drug	Company	Phase	Status
Presbyopia Treatment	Viatris (2)	NDA Submitted	Active
Presbyopia-Correcting ICL	STAAR Surgical	Research & Development	Active R&D
LB-01	Lento Bio	Discovery/IND-Enabling	Active
LB-02	Lento Bio	Discovery	Active
Presbyopia-Correcting Contact Lenses	Clerio Vision	Development	Active
Intra-corneal Implant	MAG Optics	Pre-clinical	Active
ArtiPlus	Ophtec	Clinical Trials	Active
BRIMOCHOL™ PF	Tenpoint Therapeutics	NDA Submitted	Active
Qlosi™	Orasis Pharmaceuticals	Approved	Active
TSH‑001	TSH Biopharm	Phase 1/2	Active
DE-128A	Santen Pharmaceutical	Phase 2	Active
YP-10	Viatris	NDA Filed	Under FDA Review (PDUFA date set)